CRNX Compensation

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published August 11, 2025 at 08:05 PM

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Related Questions

What is the vesting schedule for the RSU awards and what performance or time‑based milestones are tied to them? How might the market’s perception of dilution from these grants influence the stock’s price momentum over the next 30‑60 days? How will the issuance of 75,850 stock options and 53,400 RSUs affect the fully‑diluted share count and earnings per share (EPS) outlook? What is the strike price of the newly granted non‑qualified stock options and how does it compare to the current market price? Will the compensation expense associated with these grants be recognized in the upcoming quarterly earnings, and how might it impact guidance? How does the size and structure of this inducement package compare to recent equity compensation programs at peer biotech companies? Are there any lock‑up or sell‑restriction periods for the RSUs once they vest that could affect short‑term liquidity? What is the total dollar value of the grants at grant date, and how does that align with the company's historical compensation trends? Could the increased insider ownership from these grants influence future corporate governance or voting dynamics? Is there any indication that the new non‑executive hires are tied to upcoming clinical milestones or strategic initiatives?